Compare MCB & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MCB | CGEM |
|---|---|---|
| Founded | 1999 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 957.3M | 873.4M |
| IPO Year | 2017 | 2020 |
| Metric | MCB | CGEM |
|---|---|---|
| Price | $89.80 | $14.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $97.50 | $30.11 |
| AVG Volume (30 Days) | 113.7K | ★ 720.0K |
| Earning Date | 04-21-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.89% | N/A |
| EPS Growth | ★ 11.64 | N/A |
| EPS | ★ 6.62 | N/A |
| Revenue | ★ $11,053,000.00 | N/A |
| Revenue This Year | $37.22 | N/A |
| Revenue Next Year | $14.75 | $5.20 |
| P/E Ratio | $13.64 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $51.83 | $5.68 |
| 52 Week High | $97.84 | $16.74 |
| Indicator | MCB | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 68.89 | 52.98 |
| Support Level | $72.51 | $11.43 |
| Resistance Level | $97.29 | $16.74 |
| Average True Range (ATR) | 2.09 | 0.91 |
| MACD | 1.14 | 0.04 |
| Stochastic Oscillator | 94.34 | 59.74 |
Metropolitan Bank Holding Corp is a bank holding company. It provides a broad range of business, commercial, and retail banking products and services to small businesses, middle-market enterprises, public entities, and individuals in the New York metropolitan area. The services provided by the company include deposits, trade finance, cash management solutions, savings, electronic banking, cards, and others. The company also provides various lending products such as acquisition loans, construction loans, and lines of credit, for retail, office, hospitality, multifamily, mixed-use, warehouse and distribution, and specialty-use properties. The bank derives its revenue in the form of interest income on loans.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.